NCT04948411View on ClinicalTrials.gov

Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions

Carcinoma, Non-Small-Cell Lung

Trial Locations (4)

41810-011

Núcleo de Oncologia da Bahia S.A, Salvador

30380-420

Instituto Mário Penna, Belo Horizonte

01323-001

BP - A Beneficência Portuguesa de São Paulo, São Paulo

01409-003

Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo

All Listed Sponsors

lead

Latin American Cooperative Oncology Group

OTHER

NCT04948411 - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil | Biotech Hunter | Biotech Hunter